Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kathleen Brown

Clinical Cardiac Electrophysiology Pueblo, CO Medical Doctor

NPI 1881821312 CMS profile 1100132

3670 Parker Blvd., Ste 101, Pueblo, CO 81008

Open in the dashboard

General payments

$66,877

467 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathleen Brown of Pueblo, CO is reported in the CMS Open Payments database as having received $66,877 across 467 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,247 52
2024 General $24,716 77
2023 General $13,981 100
2022 General $4,403 45
2021 General $1,942 44
2020 General $1,305 68
2019 General $3,283 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathleen Brown
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Kathleen Brown were reported at $17,247. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Kathleen Brown Clinical Cardiac Electrophysiology median Middle half National median
2019 $3,283 $2,361 $585–$8,260 $163
2020 $1,305 $993 $247–$4,351 $114
2021 $1,942 $1,185 $326–$4,739 $132
2022 $4,403 $2,073 $554–$6,789 $149
2023 $13,981 $2,568 $759–$8,159 $160
2024 $24,716 $2,557 $703–$7,403 $164
2025 $17,247 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $53,900 221 payments
  2. Medtronic, Inc. $6,028 66 payments
  3. Abbott Laboratories $4,434 73 payments
  4. Medtronic Vascular, Inc. $674 31 payments
  5. Novartis Pharmaceuticals Corporation $174 9 payments
  6. Pfizer Inc. $159 8 payments
  7. Acutus Medical, Inc. $159 2 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $143 9 payments
  9. Impulse Dynamics (USA) Inc. $139 2 payments
  10. Biosense Webster, Inc. $136 2 payments
  11. Other $929 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,438 402 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,375 6 payments
  3. Consulting Fee $15,625 4 payments
  4. Travel and Lodging $15,438 55 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System $21,969 38 payments
  2. WATCHMAN FLX $18,553 15 payments
  3. General - Therapies $3,277 23 payments
  4. FARAPULSE $3,103 9 payments
  5. LINQ II $2,410 29 payments
  6. ENSITE PRECISION $1,665 13 payments
  7. WATCHMAN $1,654 33 payments
  8. Rhythmia Mapping System $1,406 7 payments
  9. Micra $1,087 7 payments
  10. Reveal LINQ $638 29 payments
  11. Other $7,474 231 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,156

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,267,546

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

40.8%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 454 $549,400
Vyndamax Tafamidis Brand 16 $541,303
Xarelto Rivaroxaban Brand 46 $60,353
Entresto Sacubitril/Valsartan Brand 23 $31,299
Jardiance Empagliflozin Brand 20 $27,998
Repatha Sureclick Evolocumab Brand 24 $15,757
Flecainide Acetate Generic 124 $7,157
Farxiga Dapagliflozin Propanediol Brand 12 $6,866
Pradaxa Dabigatran Etexilate Mesylate Brand 25 $5,060
Metoprolol Succinate Generic 206 $4,095

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$180,824

Medicare's payments for the services billed

Medicare patients

861

Average age 76

Services billed

2,931

399 women, 462 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 57%
Arthritis 48%
Ischemic heart disease 41%
Heart failure 36%
Diabetes 34%
Chronic kidney disease 32%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $38
$38 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $16
$16 — —
Repatha
  • Amgen Inc. $16
$16 24 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $10
$10 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $10
$10 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

467 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record